Our Pricing

How Quickly Does Wegovy Start Working? Complete Dose Guide

Published on: June 03, 2026

Wondering how quickly does Wegovy start working UK patients can expect results? Most people notice appetite suppression within the first week, with measurable weight loss typically emerging between weeks 4-8 of treatment [1]. At Cured Pharmacy, we provide genuine UK-licensed Wegovy from £79.00 with free clinical assessment by our UK prescribers, helping you understand what to expect at each dose level.

How Quickly Does Wegovy Start Working: What to Expect in the First Month

Wegovy contains semaglutide, a GLP-1 receptor agonist that begins working immediately after your first injection by mimicking natural hormones that regulate appetite and blood sugar [1]. However, the clinical effects you'll notice follow a predictable timeline that varies by individual.

During the first week on the 0.25mg starter dose, many patients report reduced food cravings and earlier satiety at meals. This is semaglutide binding to GLP-1 receptors in your brain and digestive system, slowing gastric emptying and reducing hunger signals [2]. Measurable weight loss on the scales typically appears between weeks 4-8, though some patients notice changes sooner.

The initial 0.25mg dose is intentionally low to allow your body to adjust to the medication and minimise gastrointestinal side effects like nausea or constipation. Clinical trials showed that gradual dose escalation significantly improved treatment tolerability whilst maintaining efficacy [1][2].

Week-by-Week Timeline: First Month on Wegovy

Week 1 (0.25mg): Most patients notice reduced appetite and smaller portion sizes. Some experience mild nausea that typically resolves within 3-5 days as your body adapts.

Weeks 2-4 (0.25mg): Appetite suppression becomes more consistent. Average weight loss during this phase ranges from 1-2% of body weight, though individual results vary considerably [1].

By the end of month one, you'll be ready to increase to 0.5mg as part of the structured dose escalation schedule recommended by the MHRA and supported by the STEP clinical trial programme [2].

Wegovy Dose Escalation Schedule: 0.25mg to 2.4mg Explained

Wegovy follows a mandatory dose escalation schedule designed to optimise both efficacy and tolerability. The UK-licensed dosing protocol requires spending at least four weeks at each dose level before increasing, allowing your body to adjust gradually whilst building therapeutic effect [2].

The complete schedule progresses as follows: 0.25mg for 4 weeks, 0.5mg for 4 weeks, 1mg for 4 weeks, 1.7mg for 4 weeks, and finally the maintenance dose of 2.4mg from week 17 onwards. This structured approach was validated in the STEP trials, which demonstrated that patients who followed the escalation schedule experienced significantly fewer discontinuations due to gastrointestinal side effects compared to faster titration [1][2].

Your UK prescriber may adjust this timeline based on your individual response and tolerability. Some patients remain on a lower dose if they achieve their weight management goals or experience persistent side effects. The 2.4mg maintenance dose represents the therapeutic target where clinical trials observed the greatest average weight reduction, but lower doses can still provide meaningful benefit [3].

When Does Wegovy Work: Peak Effectiveness and Maximum Results

Understanding Peak Effectiveness at 2.4mg

Wegovy reaches its peak effectiveness at the 2.4mg maintenance dose, typically achieved around week 17 of treatment. In the landmark STEP 1 trial, participants on 2.4mg semaglutide achieved an average body weight reduction of 14.9% over 68 weeks compared to 2.4% with placebo [1].

However, weight loss doesn't happen linearly. Most patients experience their most rapid weight reduction between weeks 20-40 of treatment, with the rate gradually slowing as they approach their individual set point. Continued treatment at the maintenance dose helps preserve weight loss and prevent regain, which clinical data shows is crucial for long-term success [3].

How Quickly Does Wegovy Start Working Compared to Other Weight Loss Treatments

When comparing how quickly does Wegovy start working UK against alternative treatments, semaglutide demonstrates a relatively gradual but sustained trajectory. Unlike older appetite suppressants that may produce rapid initial drops followed by plateaus, Wegovy's effects build progressively as you reach higher doses [2].

Saxenda (liraglutide), another GLP-1 treatment requiring daily injections, typically shows initial effects within 2-4 weeks but achieves lower total weight reduction in clinical trials — an average of 8% body weight compared to Wegovy's 14.9% [3][4]. Mounjaro (tirzepatide), the dual GIP/GLP-1 receptor agonist, demonstrated even higher efficacy in head-to-head trials, with some patients achieving over 20% weight reduction, though it follows a similar gradual dose escalation schedule [5].

Oral medications like Orlistat work through a completely different mechanism — blocking fat absorption rather than suppressing appetite — and typically produce more modest results of 5-7% weight loss. The choice between treatments depends on your medical history, BMI, previous treatment response, and personal preferences regarding injection frequency and side effect profile [4].

Factors That Influence How Quickly Wegovy Works for You

Individual Variables Affecting Response Time

Your individual response to Wegovy depends on multiple factors including baseline BMI, metabolic health, age, genetic factors, and adherence to lifestyle modifications. Clinical trials showed considerable variation in response rates, with some patients losing over 20% of body weight whilst others achieved more modest reductions [1][2].

Patients who combine Wegovy with structured dietary changes and increased physical activity typically see faster and more substantial results. The medication works by reducing appetite and cravings, but your food choices and portion control still directly impact the rate of weight loss. Similarly, individuals with insulin resistance or metabolic syndrome may experience a slightly delayed initial response as semaglutide improves their underlying metabolic dysfunction [3].

Consistency with your weekly injection schedule is crucial. Missing doses or irregular administration can delay therapeutic effect and may increase side effects when you resume treatment. If you miss a dose by more than five days, clinical guidance recommends resuming at the previous lower dose level rather than continuing at your current dose [2].

Starting Wegovy: What UK Patients Need to Know

Wegovy is a prescription-only medication in the UK, licensed by the MHRA for weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as type 2 diabetes or hypertension [2]. At Cured Pharmacy, all patients complete a free online clinical assessment reviewed by our UK-registered prescribers before treatment can be dispensed.

Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team ensure every prescription meets NICE guidelines and is clinically appropriate for your individual circumstances. The consultation takes under three minutes and covers your medical history, current medications, and weight management goals. We provide transparent upfront pricing — Wegovy is available from £79.00 — so you know the exact cost before completing your assessment.

Once approved, your Wegovy pens are dispensed from our UK-registered pharmacy (GPhC 9012511) in 100% discreet packaging with next-day delivery options available. Each pen is a genuine UK-licensed product stored and handled according to strict pharmaceutical standards. You'll receive clear injection instructions, dose escalation guidance, and ongoing support from our clinical team throughout your treatment journey.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy (semaglutide) Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary and weight loss outcomes depend on multiple factors including adherence to treatment and lifestyle modifications.